logo
Twitter
Discord
Email
logo
logo
Soleno Therapeutics, Inc.NASDAQ - SLNO
Reports
Search reports
Name
Reporting Date
Filing Date
2024-09-30 10-Q2024-09-302024-11-06
2024-06-30 10-Q2024-06-302024-08-07
2024-03-31 10-Q2024-03-312024-05-09
2023-12-31 10-K2023-12-312024-03-07
2023-09-30 10-Q2023-09-302023-11-08
2023-06-30 10-Q2023-06-302023-08-08
2023-03-31 10-Q2023-03-312023-05-09
2022-12-31 10-K2022-12-312023-03-22
2022-09-30 10-Q2022-09-302022-11-09
2022-06-30 10-Q2022-06-302022-08-10
2022-03-31 10-Q2022-03-312022-05-10
2021-12-31 10-K2021-12-312022-03-31
2021-09-30 10-Q2021-09-302021-11-10
2021-06-30 10-Q2021-06-302021-07-28
2021-03-31 10-Q2021-03-312021-05-05
2020-12-31 10-K2020-12-312021-03-03
2020-09-30 10-Q2020-09-302020-11-10
2020-06-30 10-Q2020-06-302020-08-10
2020-03-31 10-Q2020-03-312020-05-12
2019-12-31 10-K2019-12-312020-03-04
1
2
3
20 / page
About
Name
Soleno Therapeutics, Inc.
Overview
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Show More
CEO
Dr. Anish Bhatnagar M.D.
Industry
Biotechnology
Exchange
NASDAQ
Listing Date
2014-11-13
Address
203 Redwood Shores Parkway, Suite 500, Redwood City, CA, 94065, United States
Tel
650-213-8444
Website
https://soleno.life